Blend Uniformity Evaluation (BUE)

Blend Uniformity Evaluation samples the powder blend at multiple defined locations in the blender (or discharge stream) and assays each sample for active. The statistic that matters is the relative standard deviation (%RSD) of the assay results and how each location's potency compares to the target. Acceptable BUE is a prerequisite for blend release into compression, encapsulation or filling.

• Sample size targets the dose mass (1×–3× the dosage unit mass) — testing larger samples obscures segregation.
• Locations are stratified across the blender geometry — top/middle/bottom, corners, dead zones.
• Acceptance criteria are typically mean within 90.0–110.0% of label claim and %RSD ≤ 5.0%, tightened during PPQ/CPV.
• BUE is in-process — distinct from finished-dosage-unit content uniformity per USP <905>.

Powder-blend sampling is notoriously biased. The traditional sampling thief disturbs the powder bed as it enters, preferentially captures coarser or finer fractions depending on geometry, and can show false non-uniformity that disappears with stream sampling. FDA's 2003 draft guidance explicitly accepts stratified sampling at the press as an alternative when thief sampling is unrepresentative.

• Side-sampling thieves disturb less than end-loading thieves but still bias in cohesive blends.
• Stream sampling (drum/IBC discharge) collects the actual material going to the press — closer to reality.
• Wireless or NIR in-blender monitoring (PAT) removes the thief problem entirely but requires method validation under ICH Q14.

• Sampling 10× the dosage mass — masks small-scale segregation and gives false confidence.
• All samples from the top of the blender — misses bottom dead zones.
• Treating thief-sampling bias as a real result — leading to over-blending and unnecessary segregation.
• Skipping stratified press sampling for content uniformity — losing the regulator-preferred predictor.
• Using <905> limits as BUE limits — too loose; an in-process test must be tighter than the release test.
• Not investigating individual-location failures even when the mean passes — segregation hides in the spread.

• Solid oral pharma — BUE is mandatory at PPQ and routine in-process per FDA expectation.
• Dietary supplements (21 CFR 111) — equivalent uniformity testing required at the blend step per 111.110.
• Veterinary medicated feed — Type B/C medicated articles require uniformity per CVM GFI #135.
• Biopharma drug-substance powder fill — pre-fill blend uniformity supports vial-to-vial dose accuracy.
• Powder-fill cosmetics — bulk uniformity supports MoCRA stability and labelled potency claims.